Name | Title | Contact Details |
---|
Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.
The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.
SILKTECH focuses on innovating and developing silk-derived protein (SDP) products for ophthalmic applications. The company`s patented SDP material is currently being developed as a novel compound for the treatment of patients with dry eye disease. SILKTECH is based in Plymouth, MN and is financially backed by a combination of angels, grants and recently from a financing round by Skyview Ventures LLC.
Osage Bio Energy is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Primorigen Biosciences LLC is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.